MorphoSys AG (MORG.DE)
MORG.DE on Xetra
110.50EUR
3:32pm BST
110.50EUR
3:32pm BST
Change (% chg)
€1.60 (+1.47%)
€1.60 (+1.47%)
Prev Close
€108.90
€108.90
Open
€110.50
€110.50
Day's High
€111.60
€111.60
Day's Low
€109.10
€109.10
Volume
56,525
56,525
Avg. Vol
151,020
151,020
52-wk High
€114.60
€114.60
52-wk Low
€76.45
€76.45
About
MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietar... (more)
Overall
| Beta: | 0.78 |
| Market Cap(Mil.): | €2,171.58 |
| Shares Outstanding(Mil.): | 29.35 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| MORG.DE | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 69.38 | 32.67 |
| EPS (TTM): | -2.61 | -- | -- |
| ROI: | -19.28 | 8.94 | 14.48 |
| ROE: | -19.78 | 10.07 | 15.78 |
CORRECTED-BRIEF-Morphosys Confirms Higher 2019 Revenue Guidance
* Financial year 2019 guidance, updated in July, confirmed: revenues in range of 65 mln to 72 mln eur
German stocks - Factors to watch on May 22
BERLIN/FRANKFURT, May 22 The following are some of the factors that may move German stocks on Wednesday:
German stocks - Factors to watch on April 30
BERLIN, April 30 The following are some of the factors that may move German stocks on Tuesday:
BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study
* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
German biotech group Morphosys seeks European partner for debut drug
FRANKFURT, Feb 25 German biotech firm Morphosys is in talks with potential partners to bring its debut drug, a therapeutic antibody against leukaemia, to Europe.
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.✕
Estimates